JP4690317B2 - 尿酸塩と子癇前症の検出とを関連付ける方法 - Google Patents
尿酸塩と子癇前症の検出とを関連付ける方法 Download PDFInfo
- Publication number
- JP4690317B2 JP4690317B2 JP2006516413A JP2006516413A JP4690317B2 JP 4690317 B2 JP4690317 B2 JP 4690317B2 JP 2006516413 A JP2006516413 A JP 2006516413A JP 2006516413 A JP2006516413 A JP 2006516413A JP 4690317 B2 JP4690317 B2 JP 4690317B2
- Authority
- JP
- Japan
- Prior art keywords
- urate
- sample
- saliva
- preeclampsia
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims description 108
- 201000011461 pre-eclampsia Diseases 0.000 title claims description 35
- 238000001514 detection method Methods 0.000 title claims description 4
- 239000000523 sample Substances 0.000 claims description 29
- 210000003296 saliva Anatomy 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 22
- 238000012360 testing method Methods 0.000 claims description 18
- 238000003556 assay Methods 0.000 claims description 16
- 239000012472 biological sample Substances 0.000 claims description 15
- 238000012545 processing Methods 0.000 claims description 4
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 23
- 229940116269 uric acid Drugs 0.000 description 23
- 239000008280 blood Substances 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 22
- 239000003153 chemical reaction reagent Substances 0.000 description 16
- 230000035935 pregnancy Effects 0.000 description 15
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 14
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N 4-aminoantipyrine Chemical compound CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 10
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 6
- 230000002060 circadian Effects 0.000 description 6
- 230000029142 excretion Effects 0.000 description 5
- 230000036542 oxidative stress Effects 0.000 description 5
- LWKJNIMGNUTZOO-UHFFFAOYSA-N 3,5-dichloro-2-hydroxybenzenesulfonic acid Chemical compound OC1=C(Cl)C=C(Cl)C=C1S(O)(=O)=O LWKJNIMGNUTZOO-UHFFFAOYSA-N 0.000 description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 108010092464 Urate Oxidase Proteins 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000001605 fetal effect Effects 0.000 description 4
- 230000008774 maternal effect Effects 0.000 description 4
- 150000007968 uric acids Chemical class 0.000 description 4
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 229960000458 allantoin Drugs 0.000 description 3
- 230000036765 blood level Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- LWKJNIMGNUTZOO-UHFFFAOYSA-M 3,5-dichloro-2-hydroxybenzenesulfonate Chemical compound OC1=C(Cl)C=C(Cl)C=C1S([O-])(=O)=O LWKJNIMGNUTZOO-UHFFFAOYSA-M 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 201000001431 Hyperuricemia Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000012445 acidic reagent Substances 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000032696 parturition Effects 0.000 description 2
- 201000001474 proteinuria Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- XDKLKFULWJYRCB-UHFFFAOYSA-N 7,9-dihydro-3h-purine-2,6,8-trione;sodium Chemical compound [Na].N1C(=O)NC(=O)C2=C1NC(=O)N2 XDKLKFULWJYRCB-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 206010018985 Haemorrhage intracranial Diseases 0.000 description 1
- 208000037319 Hepatitis infectious Diseases 0.000 description 1
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 1
- 208000011948 Multi-organ disease Diseases 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000002358 circulating endothelial cell Anatomy 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000012332 laboratory investigation Methods 0.000 description 1
- 208000037805 labour Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/145555—Hetero-N
- Y10T436/147777—Plural nitrogen in the same ring [e.g., barbituates, creatinine, etc.]
- Y10T436/148888—Uric acid
Description
尿酸塩は小さい分子であり、唾液を含めた細胞外流体中に広く散在している。唾液尿酸塩は(腎臓におけるように)再吸収されないが、嚥下され、腸内細菌により分解される。よって、血液尿酸塩濃度が有意に変化しなくても唾液中の尿酸塩産生の迅速変化または急激変化が検出される。
(1)被験者から生体サンプルを採取し、場合によりこのサンプルを10℃以下で保存するステップ、
(2)アッセイにかける前に生体サンプルを処理するステップ、
(3)サンプルを存在する尿酸塩濃度についてアッセイするステップ、
(4)(3)で得た結果を正常な対照値と比較して、子癇前症を診断するステップ
を含む子癇前症の診断方法が提供される。
歯磨きまたは食事を取る前に、女性は滅菌Salivette(登録商標)管(図5)(2)から綿棒(1)を取り出す。Salivette(登録商標)は、綿棒を入れるための底部に孔を有するインサートを有するプラスチック製使い捨て遠心管である。これは本発明にとって重要でないが、本発明者らは乾燥検査スティックまたは適当な試薬をコーティングしたディップスティックのような他の唾液サンプリング及び検査方法が開発されると予測している。女性は綿棒を舌の下に入れて綿棒を湿らせた後、約45秒間舌の上でやさしく噛む。こうすると、口内で唾液分泌が活性化され、綿棒は混合唾液を吸収する。次いで、サンプルの安全な保存を確保すべく適切にラベリングしたSalivette(登録商標)のインサートに綿棒を戻す。次いで、運んで、検査室で処理するまで通常の家庭用冷蔵庫において約4℃で冷却する。
検査室で受領し、その後患者の情報を管のラベルから集めた後、綿棒インサートを含むSalivette(登録商標)管を3000回転で5分間遠心する。混合唾液(3)の透明なサンプルはすぐにアッセイにかけることができる。或いは、綿棒インサートを圧縮することによりアッセイ用サンプルを作成してもよい。アッセイは、±5%の精度を与え、30〜1000μmol/lの値の範囲内で読みとることができる任意の方法により実施され得る。しかしながら、完全とするために、市販されているマルチテスターのSYNCHRON CXシステムマルチキャリブレーターを用いる方法を以下に説明する。
血液尿酸塩と比較した唾液尿酸塩の感受性を評価する際(図2)、24時間にわたり2時間毎の尿酸塩濃度の結果をKanabrockiらの血清尿酸塩データと比較した。唾液尿酸塩は血清尿酸塩の日内変動と相関しており、夜には上昇した。血清の24時間範囲は380〜405μmol/l、すなわちたった25μmol/lの変動しかなかったのに対して、唾液の結果は125〜350μmol/l、すなわち225μmol/lの範囲に増幅された。
Many A., Hubel CA., Roberts JM., Hyperuricaemia and xanthine oxidase in preeclampsia, revisited, American Journal of Obstetrics and Gynaecology 174(1), 288-291 (1996)、
Chappell LC., Seed PT., Briley AL., Kelly FJ., Hunt BJ., JH.,Charnock-Jones S., Mallet AI., Poston L. A longitudinal study of biochemical variables in women at risk of preeclampsia, American Journal of Obstetrics and Gynaecology, 186, 127-136 (2002)、
Sorensen LB., The elimination of uric acid in man studied by means of C14-labelled uric acid, Scandinavian Journal of Clinical Laboratory Investigation, 補遺: 54 (1960)、
Owen-Smith BD及びWhyman A., Diurnal and nocturnal variations of enteral uricolysis during fasting and refeeding, (Abstract), Annals of Rheumatic Diseases, 40, 523-524 (1981)、
Kanabrocki EL., Third J., Ryan MD., Nemchausky BA., Shirazi P., Scheving LE., Hines E Jr.,McCormick JB, Circadian relationships of serum uric acid and nitric oxide, Journal of the American Medical Association, 283: 2240-2241 (2000)、
Owen-Smith BD, Significance of variations of uric acid elimination Annals of Rheumatic Diseases, 42, 補遺: 87 (1983)、
Owen-Smith BD., Quiney, J & Read J., Salivary urate in gout, exercise and diurnal variation, Lancet, 351:1932 (1998)。
Claims (5)
- 妊婦唾液からの生体サンプルにおける尿酸塩と子癇前症の検出とを関連付ける方法であって、以下のステップを含む方法:
(1)被験者から生体サンプルを採取するステップ、
(2)アッセイにかける前に前記生体サンプルを処理するステップ、
(3)存在する尿酸塩の濃度について前記サンプルをアッセイするステップ、および
(4)(3)で得た結果と正常な対照値とを比較するステップ。 - 尿酸塩を時間エンドポイント法によりアッセイする請求項1に記載の方法。
- 尿酸塩を乾燥検査法によりアッセイする請求項1に記載の方法。
- 尿酸塩をディップスティック法によりアッセイする請求項1に記載の方法。
- 妊婦唾液中の尿酸塩レベルの子癇前症の指標としての使用であって、子癇前症の検出が以下のステップを含む使用:
(1)被験者から生体サンプルを採取するステップ、
(2)アッセイにかける前に前記生体サンプルを処理するステップ、
(3)存在する尿酸塩の濃度について前記サンプルをアッセイするステップ、および
(4)(3)で得た結果と正常な対照値とを比較するステップ。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0313828.6 | 2003-06-16 | ||
GBGB0313828.6A GB0313828D0 (en) | 2003-06-16 | 2003-06-16 | Salivary urate for diagnosis of pre-eclampsia |
PCT/GB2004/002521 WO2004113926A2 (en) | 2003-06-16 | 2004-06-11 | Diagnosis of pre-eclampsia |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006527847A JP2006527847A (ja) | 2006-12-07 |
JP4690317B2 true JP4690317B2 (ja) | 2011-06-01 |
Family
ID=27636558
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006516413A Active JP4690317B2 (ja) | 2003-06-16 | 2004-06-11 | 尿酸塩と子癇前症の検出とを関連付ける方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US7763440B2 (ja) |
EP (1) | EP1634082B1 (ja) |
JP (1) | JP4690317B2 (ja) |
ES (1) | ES2394309T3 (ja) |
GB (1) | GB0313828D0 (ja) |
PL (1) | PL1634082T3 (ja) |
WO (1) | WO2004113926A2 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005093413A2 (en) * | 2004-03-22 | 2005-10-06 | Yale University | Diagnosis and treatment of preeclampsia |
US20120101021A1 (en) | 2009-02-06 | 2012-04-26 | Surendra Sharma | Compositions, formulations and methods of treating preeclampsia-type disorders of pregnancy |
GB201316668D0 (en) * | 2013-09-19 | 2013-11-06 | Salurate Linited | Diagnosis of foetal distress |
JP7018023B2 (ja) * | 2016-04-14 | 2022-02-09 | モーガン イノベーション アンド テクノロジー リミテッド | 体液中の被分析物のレベルを測定するための方法およびデバイス |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5849474A (en) | 1995-12-06 | 1998-12-15 | Olson; Camilla M. | Diagnosis of preeclampsia in mammals |
US6753159B1 (en) * | 1998-08-06 | 2004-06-22 | Jin Po Lee | Uric acid assay device with stabilized uricase reagent composition |
CA2306554A1 (en) * | 1998-08-06 | 2000-02-17 | Jin Po Lee | Uric acid assay device with stabilized uricase reagent composition |
US7191068B2 (en) | 2003-03-25 | 2007-03-13 | Proteogenix, Inc. | Proteomic analysis of biological fluids |
-
2003
- 2003-06-16 GB GBGB0313828.6A patent/GB0313828D0/en not_active Ceased
-
2004
- 2004-06-11 WO PCT/GB2004/002521 patent/WO2004113926A2/en active Application Filing
- 2004-06-11 PL PL04736663T patent/PL1634082T3/pl unknown
- 2004-06-11 EP EP04736663A patent/EP1634082B1/en active Active
- 2004-06-11 ES ES04736663T patent/ES2394309T3/es active Active
- 2004-06-11 JP JP2006516413A patent/JP4690317B2/ja active Active
- 2004-06-11 US US10/560,954 patent/US7763440B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US7763440B2 (en) | 2010-07-27 |
GB0313828D0 (en) | 2003-07-23 |
JP2006527847A (ja) | 2006-12-07 |
US20070020766A1 (en) | 2007-01-25 |
EP1634082B1 (en) | 2012-09-05 |
WO2004113926A2 (en) | 2004-12-29 |
EP1634082A2 (en) | 2006-03-15 |
ES2394309T3 (es) | 2013-01-30 |
PL1634082T3 (pl) | 2013-02-28 |
WO2004113926A3 (en) | 2005-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Jung et al. | Urinary enzymes and low-molecular-mass proteins as indicators of diabetic nephropathy. | |
JP2013506833A (ja) | 低酸素誘導性の細胞損傷を測定する検査システム | |
Sink et al. | Practical veterinary urinalysis | |
AU2004240557A1 (en) | Apparatus and method for risk stratification of patients with chest pain of suspected cardiac origin | |
WO2013008239A1 (en) | Noninvasive detection of meconium in amniotic fluid | |
Apple et al. | Lipase and pancreatic amylase activities in tissues and in patients with hyperamylasemia | |
JP2008547001A (ja) | レシオメトリック試験ストリップおよび方法 | |
JP4690317B2 (ja) | 尿酸塩と子癇前症の検出とを関連付ける方法 | |
O'BRIEN | The prediction of preeclampsia | |
Shimada et al. | Sex‐determining region Y levels in maternal plasma: Evaluation in abnormal pregnancy | |
US6461830B1 (en) | Determining existence of preeclampsia in pregnancies by measuring levels of glycerophosphatidyl compounds, glycerophosphatidycholine, lysophospholipids and lysophosphatidylcholine | |
Peiris | The value of serum fructosamine in comparison with oral glucose tolerance test (OGTT) as a screening test for detection of gestational diabetes mellitus | |
Nordström et al. | Fetal scalp and umbilical artery blood lactate measured with a new test strip method | |
Aisen et al. | A rapid screening test for deficiency of plasma ceruloplasmin and its value in the diagnosis of Wilson's disease | |
Coad et al. | Understanding urinalysis: clues for the obstetrician–gynecologist | |
US7399596B2 (en) | Method for predicting pregnancy-induced hypertension | |
EP0290217B1 (en) | An in vitro diagnostic method | |
Ryley et al. | Screening for cystic fibrosis in the newborn by meconium analysis. | |
JP2003530069A (ja) | ジサッカライドの評価法及び評価用キット | |
Vucijak-Grgurevic et al. | Significance of nitric oxyde saliva concentration of the patients with renal failure on hemodialysis | |
Schröder et al. | Clinical value of detecting microalbuminuria as a risk factor for pregnancy-induced hypertension in insulin-treated diabetic pregnancies | |
Bhuvaneswari et al. | Comparison of Serum Urea, Salivary Urea, and Creatinine Levels in Pre-Dialysis and Post-Dialysis Patients: A Case-Control Study | |
Pulkkinen et al. | Pancreatic and catalytic phospholipase A2 in relation to pregnancy, labor and fetal outcome | |
McIntyre et al. | Lag times between blood sampling, spinning and plasma glucose estimation | |
Parker et al. | Suspected hypoglycaemia in out patient practice: accuracy of dried blood spot analysis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070523 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090929 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091218 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091228 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100329 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100914 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101210 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110118 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110217 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 4690317 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140225 Year of fee payment: 3 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140225 Year of fee payment: 3 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |